Digital Therapeutics are revolutionizing healthcare. Innovative digital technologies are enabling novel mechanisms of action to be deployed to nearly anywhere in the world. The last five years have demonstrated their need and promise; digital therapeutics are already providing effective, personalized, scalable, evidence-based treatments for the management of chronic mental and physical health conditions. Due to the increasing demand for digital treatments and tools by patients and care teams, healthcare systems are establishing novel evaluation criteria to guide their use. This Research Topic will serve as a resource and outlet for academic and industry pioneers of digital therapeutics. We welcome submissions across the evidence spectrum, ranging from studies of component technologies (e.g., sensors, algorithms, and software) to clinical trials and reviews.
There are two problems we would like to address in this Research Topic. First, advances in digital technologies are enabling access to timely, personalized, and high-quality interventions; better management of chronic health conditions; scalable evidence-based treatments; and the generation of large datasets that can inform care delivery and health policy. To keep pace with the rapid expansion of the digital therapeutics industry, this research collection will exhibit and incite innovation of novel digital therapeutics and their component technologies, such as sensors, algorithms, and software. Second, recent advancements in the pursuit of public payor coverage of digital therapeutics—such as the recent announcement by Massachussett's Medicaid program of their intention to cover two prescription digital therapeutics—we anticipate a growing number of digital therapeutics to pursue commercialization strategies that include coverage by public payors and pharmacy benefits managers. However, as federal and state agencies assess digital treatments, there is a need to converge on gold-standard outcomes and endpoints that convey clinical, functional, and health economic impact. As we witness a handful of digital therapeutics companies transition from pre-commercial to commercial stages, with buy-in from payor groups, this research collection will showcase outcome measurements that meet the needs of all stakeholders.
The themes we would like contributors to address are cross-expertise collaboration, functional outcomes, clinical outcomes, FDA authorization, health improvement, disease management, disease treatment, disease prevention, endpoints, comorbidities, cost savings, and rehabilitation. The types of manuscripts we are interested in are manuscripts that are co-written by people across different stages of the digital therapeutics commercialization pipeline; expert reviews; early feasibility results; clinical trial results, especially those that have pre-registered their analyses; sensor technology; outcome, endpoint, and psychometric validations; health economic outcomes research; and meta-analyses on outcomes and endpoints, especially those that establish relevant evidence for both clinical and reimbursement purposes.
---
Dr. Sabrina Taylor and Dr. Kirsten Smayda are affiliated with and hold shares in the private company MedRhythms. Dr. Louis Awad is a compensated consultant with MedRhythms. Dr. Timothy Campellone is affiliated with the private company Click Therapeutics.
Digital Therapeutics are revolutionizing healthcare. Innovative digital technologies are enabling novel mechanisms of action to be deployed to nearly anywhere in the world. The last five years have demonstrated their need and promise; digital therapeutics are already providing effective, personalized, scalable, evidence-based treatments for the management of chronic mental and physical health conditions. Due to the increasing demand for digital treatments and tools by patients and care teams, healthcare systems are establishing novel evaluation criteria to guide their use. This Research Topic will serve as a resource and outlet for academic and industry pioneers of digital therapeutics. We welcome submissions across the evidence spectrum, ranging from studies of component technologies (e.g., sensors, algorithms, and software) to clinical trials and reviews.
There are two problems we would like to address in this Research Topic. First, advances in digital technologies are enabling access to timely, personalized, and high-quality interventions; better management of chronic health conditions; scalable evidence-based treatments; and the generation of large datasets that can inform care delivery and health policy. To keep pace with the rapid expansion of the digital therapeutics industry, this research collection will exhibit and incite innovation of novel digital therapeutics and their component technologies, such as sensors, algorithms, and software. Second, recent advancements in the pursuit of public payor coverage of digital therapeutics—such as the recent announcement by Massachussett's Medicaid program of their intention to cover two prescription digital therapeutics—we anticipate a growing number of digital therapeutics to pursue commercialization strategies that include coverage by public payors and pharmacy benefits managers. However, as federal and state agencies assess digital treatments, there is a need to converge on gold-standard outcomes and endpoints that convey clinical, functional, and health economic impact. As we witness a handful of digital therapeutics companies transition from pre-commercial to commercial stages, with buy-in from payor groups, this research collection will showcase outcome measurements that meet the needs of all stakeholders.
The themes we would like contributors to address are cross-expertise collaboration, functional outcomes, clinical outcomes, FDA authorization, health improvement, disease management, disease treatment, disease prevention, endpoints, comorbidities, cost savings, and rehabilitation. The types of manuscripts we are interested in are manuscripts that are co-written by people across different stages of the digital therapeutics commercialization pipeline; expert reviews; early feasibility results; clinical trial results, especially those that have pre-registered their analyses; sensor technology; outcome, endpoint, and psychometric validations; health economic outcomes research; and meta-analyses on outcomes and endpoints, especially those that establish relevant evidence for both clinical and reimbursement purposes.
---
Dr. Sabrina Taylor and Dr. Kirsten Smayda are affiliated with and hold shares in the private company MedRhythms. Dr. Louis Awad is a compensated consultant with MedRhythms. Dr. Timothy Campellone is affiliated with the private company Click Therapeutics.